Biogen stock closes 0.55 percent higher as Q2 growth holds

Biogen stock (ISIN US09062X1037) closed at USD 227.60 on Nasdaq on September 25, 2026, gaining 0.55 percent and sitting 0.69 percent below its 52-week high of USD 229.19. The latest market reference follows second-quarter results that gave the biotechnology company a stronger earnings base.

Q2 revenue beats expectations

According to MarketBeat, Biogen reported adjusted EPS of USD 3.60 for Q2 2026, exceeding the USD 2.94 consensus by USD 0.66. Revenue reached USD 2.74 billion versus expectations of USD 2.46 billion, while quarterly revenue increased 3.40 percent year over year.

The earnings mix matters because the comparison combines a higher revenue base with a clear adjusted-EPS beat. Biogen's Q2 performance therefore offers a more concrete support point for the current valuation than the share-price move alone.

Analyst target leaves limited upside

MarketBeat lists a Moderate Buy consensus based on 32 analyst ratings and an average 12-month price target of USD 230.14. Against the September 25 price of USD 227.60, that target is 1.12 percent higher, while the published target range extends from USD 175.00 to USD 300.00.

The narrow gap between the closing price and the average target puts greater weight on execution and upcoming clinical milestones. In the Q2 2026 earnings transcript, Fortune reported that management expects five registrational study readouts across SLE, CLE, AMR and Dravet syndrome over the next several quarters.

October results set the next checkpoint

Biogen has announced through its investor-relations release that it will report third-quarter 2026 financial results before the market opens on October 28, 2026, according to Biogen. The date gives investors a defined checkpoint for revenue momentum, product launches and pipeline progress.

Biogen stock stays near yearly high

Biogen stock closed at USD 227.60 on Nasdaq on September 25, 2026, with a market capitalization of USD 33.6 billion and volume of 958,030 shares. Its 52-week range was USD 135.39 to USD 229.19, leaving the stock 67.76 percent above its level one year earlier.

More news and analyses on Biogen stock